CN115151264B - 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法 - Google Patents

用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法 Download PDF

Info

Publication number
CN115151264B
CN115151264B CN202080083041.5A CN202080083041A CN115151264B CN 115151264 B CN115151264 B CN 115151264B CN 202080083041 A CN202080083041 A CN 202080083041A CN 115151264 B CN115151264 B CN 115151264B
Authority
CN
China
Prior art keywords
backbone
compound
therapeutic
glucan
mannosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080083041.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115151264A (zh
Inventor
D·A·拉尔夫
J·阿诺尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of CN115151264A publication Critical patent/CN115151264A/zh
Application granted granted Critical
Publication of CN115151264B publication Critical patent/CN115151264B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN202080083041.5A 2019-09-30 2020-09-30 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法 Active CN115151264B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908136P 2019-09-30 2019-09-30
US62/908136 2019-09-30
PCT/US2020/053604 WO2021067479A1 (en) 2019-09-30 2020-09-30 Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands

Publications (2)

Publication Number Publication Date
CN115151264A CN115151264A (zh) 2022-10-04
CN115151264B true CN115151264B (zh) 2024-03-12

Family

ID=75337533

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083041.5A Active CN115151264B (zh) 2019-09-30 2020-09-30 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法

Country Status (7)

Country Link
US (1) US20210145989A1 (https=)
EP (1) EP4021459A4 (https=)
JP (1) JP7599727B2 (https=)
CN (1) CN115151264B (https=)
CA (1) CA3155675A1 (https=)
MX (1) MX2022003699A (https=)
WO (1) WO2021067479A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CN114894698B (zh) * 2022-04-15 2023-02-03 广东省第二人民医院（广东省卫生应急医院） MDSCs在再生障碍性贫血诊断和/或分型中的应用
EP4554984A1 (en) * 2022-07-13 2025-05-21 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624046A (en) * 1982-01-04 1986-11-25 Fairchild Camera & Instrument Corp. Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM
JP3582234B2 (ja) * 1996-05-20 2004-10-27 ニプロ株式会社 ＩｇＡ腎症特異的フィブロネクチン断片、その検出方法およびキット
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
AU2003267872A1 (en) * 2002-05-06 2003-11-11 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
JP4543860B2 (ja) * 2004-09-30 2010-09-15 株式会社島津製作所 試料の解析方法
US20080004237A1 (en) * 2006-02-23 2008-01-03 Tam Joemy C Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers
WO2012171035A1 (en) * 2011-06-10 2012-12-13 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
CA3064277A1 (en) * 2017-05-19 2018-11-22 Navidea Biopharmaceuticals, Inc. Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Preparation of Tc-99m-Labeled Mannan-S-Cysteine and Effect of Molecular Size of Mannan on Its Biodistribution;Hagiwara, Yuki et al.;《Biological & pharmaceutical bulletin》;第42卷(第5期);第819-826页 *
巨噬细胞甘露糖受体与配体亲和力检测方法的建立与应用;吕正光,刘莉,刘新友,等;《中国医药指南》;第9卷(第30期);第215-217页 *

Also Published As

Publication number Publication date
CA3155675A1 (en) 2021-04-08
WO2021067479A1 (en) 2021-04-08
US20210145989A1 (en) 2021-05-20
JP7599727B2 (ja) 2024-12-16
JP2022550174A (ja) 2022-11-30
EP4021459A4 (en) 2023-09-27
MX2022003699A (es) 2022-07-13
EP4021459A1 (en) 2022-07-06
CN115151264A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
CN115151264B (zh) 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
ES2788865T3 (es) Conjugados farmacéuticos de nanopartículas
AU2019390489B2 (en) Dendrimer for therapy and imaging
US9539345B2 (en) Method to improve the tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting
US12178829B2 (en) Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
WO2021123013A1 (de) Smart-drug-delivery-system und pharmazeutisches kit für duale nuklearmedizinisch-cytotoxische theranostik
WO2020055455A1 (en) Targeted nanoparticles for diagnosing, detecting, and treating cancer
US12186404B2 (en) Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
CA3095137A1 (en) Pharmaceutical compositions containing polyrotaxanes
CN114555131A (zh) 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
US20230302041A1 (en) Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
EP4076540A1 (en) Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
US20250382392A1 (en) Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
US20220001038A1 (en) Conjugates for detection of axillary lymph node metastases
HK1167869A1 (zh) 纳米级铂化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant